Document Detail


End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease.
MedLine Citation:
PMID:  17219034     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The study was designed to investigate the possible occurrence of "wearing-off" (WO) during dopamine agonist (DA) monotherapy. Sixty patients with "de novo" idiopathic PD were randomised into one of two DA monotherapy branches to receive oral ropinirole at 15 mg per day, or pramipexole at 2.1 mg per day. DA doses could be increased in the following two years but levodopa could not be added until the study ended. WO was assessed by self-evaluation charts confirmed by a blinded observation of a 30% or greater deterioration in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score. Proc Mixed and Kaplan-Meier curves evaluated treatment variables as a function of time. T-tests were used to compare post-hoc variables reclassified according to WO occurrence. Thirty patients received ropinirole, and 30 pramipexole monotherapy. Eighteen patients (30%) experienced "wearing-off" 15-21 months after beginning monotherapy. No differences were observed between treatments. WO phenomena was observed 3.4+/-0.3 hours after intake of the morning or afternoon dose and consisted of UPDRS score worsening by 11.1+/-2.1 points (69-111% more than "on" score). Statistical evaluation gave evidence of differences between patients who experienced WO and those who did not: UPDRS motor scores obtained at admission to the study were higher (by 3.4+/-0.2 points, p=0.01 t-test) and DA doses at 6-12 months were higher in fluctuating patients. UPDRS motor scores deteriorated, however. similarly and there were no differences, in UPDRS scores recorded in ON conditions, between fluctuating and non-fluctuating patients at the end of the study. Our findings provide evidence of WO phenomena in patients with early PD receiving non-ergolinic DA monotherapy.
Authors:
Astrid Thomas; Laura Bonanni; Angelo Di Iorio; Sara Varanese; Francesca Anzellotti; Anna D'Andreagiovanni; Fabrizio Stocchi; Marco Onofrj
Related Documents :
20972124 - Poh04 treatment of medically intractable sunct and suna with occipital nerve stimulation.
21111314 - Natural history of corneal haze after collagen crosslinking for keratoconus and corneal...
22123344 - Central line "attention" is their best prevention.
21539554 - Morphological development of larval cobia rachycentron canadum and the influence of die...
20970794 - Prokinetics in acute upper gi bleeding: a meta-analysis.
20176434 - A randomized comparison of cardiocerebral and cardiopulmonary resuscitation using a swi...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of neurology     Volume:  253     ISSN:  0340-5354     ISO Abbreviation:  J. Neurol.     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2007-01-12     Completed Date:  2007-06-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0423161     Medline TA:  J Neurol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1633-9     Citation Subset:  IM    
Affiliation:
Neurophysiopathology, Movement Disorders Center, Department of Oncology and Neuroscience, University G.D'Annunzio Chieti-Pescara, Ospedale Civile di Pescara, via Fonte Romana, 65124, Pescara, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Benzothiazoles / adverse effects*
Dopamine Agonists / adverse effects*
Double-Blind Method
Endpoint Determination / methods
Female
Humans
Indoles / adverse effects*
Longitudinal Studies
Male
Middle Aged
Parkinson Disease / drug therapy*,  physiopathology
Parkinson Disease, Secondary / chemically induced*
Severity of Illness Index
Time Factors
Chemical
Reg. No./Substance:
0/Benzothiazoles; 0/Dopamine Agonists; 0/Indoles; 104632-26-0/pramipexol; 91374-21-9/ropinirole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Contrast-enhanced ultrasound in dermatomyositis- and polymyositis.
Next Document:  A decade of breast cancer screening in The Netherlands: trends in the preoperative diagnosis of brea...